Rainer Sturm (49) is the new CFO of the HMNC Holding. Mr. Sturm has 25 years of experience in financial management of corporate and start-up companies, as well as in the venture capital industry. He started his career in the Bertelsmann Group and moved to the life science industry in 2008. As Vice President Finance of Global Life Science Ventures, a leading venture capital fund in the life science sector, he managed a number of transactions in the field of equity and mezzanine financing, as well as various exits, including an IPO on Nasdaq.

Most recently, Mr. Sturm was CFO of the international diagnostics company numares AG. During his time as CFO, several capital measures were implemented to finance growth, as well as successfully making the step from R&D company to commercialization.

"We are very pleased to have with Rainer Sturm as a new member of the management board a financial expert on board who has extensive experience in the further development of innovative and fast-growing companies, so that HMNC is now also well-equipped on the financial side to further develop its innovative technology and successfully bring it to market," says Prof. Dr. Dr. h.c. mult Holsboer, CEO and founder of HMNC.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.


Alexander Schmidt (Europa)
+49 151 22 99 39 765[at]gaulyadvisors[dot]com

Anne Donohoe (U.S.A.)
+1 212-896-1265

Investor Contact (U.S.A.)

Tim Regan
+1 347-487-6788